Answers are grounded in this paper and cite their sources.
This research demonstrates iPSC-derived iNKT cells enhance hematopoiesis in bone marrow, suggesting improved HSC transplantation outcomes.
Human invariant natural killer T (iNKT) cells are a conserved population of innate-like T cells that are activated by glycolipid antigens. In addition to their well-known role in anti-tumor function, iNKT cells are also involved in regulating and maintaining hematopoiesis in the bone marrow. Here, we present the reprogramming of human CD4 + Vα24 + Vβ11 + iNKT cells into induced pluripotent stem cells (iNKT-iPSCs) and describe a novel chemically defined, feeder-free 3D spheroid method for generating CD34 + cells from iNKT-iPSCs, followed by their re-differentiation into functional Vα24 + Vβ11 + iNKT cells (i-iNKT) with pro-hematopoietic activity. The i-iNKT cells showed specific binding to CD1d tetramers loaded with the lipid antigen α-galactosylceramide and had a similar transcription factor profile to that of somatic CD4 + iNKT cells. Additionally, in response to CD3 stimulation, the i-iNKT cells produced cytokines with hematopoietic potential and promoted expansion/differentiation of myeloid progenitors. These findings suggest the feasibility of using iPSCs as off-the-shelf i-iNKT cell sources to enhance the hematopoietic activity of bone marrow after hematopoietic stem cell (HSC) transplantation.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: